Van Cleef Asset Management Inc raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 94.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 129,752 shares of the biopharmaceutical company’s stock after buying an additional 63,096 shares during the period. Gilead Sciences comprises approximately 2.3% of Van Cleef Asset Management Inc’s investment portfolio, making the stock its 12th biggest holding. Van Cleef Asset Management Inc’s holdings in Gilead Sciences were worth $9,295,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in the business. FMR LLC increased its stake in shares of Gilead Sciences by 1.1% during the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after purchasing an additional 258,005 shares during the period. Macquarie Group Ltd. increased its stake in shares of Gilead Sciences by 26.6% during the third quarter. Macquarie Group Ltd. now owns 479,332 shares of the biopharmaceutical company’s stock worth $38,836,000 after purchasing an additional 100,741 shares during the period. Vanguard Group Inc. increased its stake in shares of Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after purchasing an additional 2,148,697 shares during the period. Northern Trust Corp increased its stake in shares of Gilead Sciences by 0.7% during the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after purchasing an additional 116,780 shares during the period. Finally, Toronto Dominion Bank increased its stake in shares of Gilead Sciences by 19.0% during the second quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock worth $33,445,000 after purchasing an additional 75,364 shares during the period. Hedge funds and other institutional investors own 77.96% of the company’s stock.
In other news, EVP James R. Meyers sold 100,000 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $80.24, for a total value of $8,024,000.00. Following the completion of the transaction, the executive vice president now directly owns 102,715 shares in the company, valued at approximately $8,241,851.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $73.87, for a total value of $1,108,050.00. Following the completion of the transaction, the executive vice president now owns 64,613 shares of the company’s stock, valued at $4,772,962.31. The disclosure for this sale can be found here. In the last ninety days, insiders sold 430,268 shares of company stock worth $34,074,395. Company insiders own 1.30% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $81.72 on Wednesday. The firm has a market capitalization of $106,186.01, a price-to-earnings ratio of 9.49, a price-to-earnings-growth ratio of -1.86 and a beta of 1.24. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $89.54. The company has a quick ratio of 2.67, a current ratio of 2.74 and a debt-to-equity ratio of 1.53.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.67 by $0.11. The firm had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The company’s revenue was down 18.7% compared to the same quarter last year. During the same quarter last year, the business posted $2.70 EPS. equities research analysts expect that Gilead Sciences, Inc. will post 6.21 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.79%. The ex-dividend date of this dividend is Thursday, March 15th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio (DPR) is currently 59.77%.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/03/14/gilead-sciences-inc-gild-shares-bought-by-van-cleef-asset-management-inc.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.